DNA Methylation Biomarker Panel for Early CRC Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tools for detecting colorectal cancer (CRC) and advanced adenoma are insufficient, leading to high mortality rates despite the availability of screening and diagnostic methods.
Innovation Solution
Utilizing DNA methylation markers, particularly in promoter regions of tumor suppressor genes, combined with fragment size analysis of cell-free DNA, to develop a biomarker panel for accurate detection and stratification of CRC and advanced adenoma.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current screening tools are used for colorectal cancer detection, then the screening process is simple and widely available, but the detection accuracy is insufficient leading to high mortality rates
Solution Approach 1:
The invention segments the detection process into multiple independent methylation marker assays, each targeting specific genes (e.g., APC, KRAS, TP53, SMAD4) with distinct methylation patterns. This allows the complex detection task to be divided into manageable components that can be measured separately and combined for comprehensive diagnosis, thereby improving detection accuracy without overwhelming system complexity
Solution Approach 2:
The invention creates a composite biomarker panel combining multiple DNA methylation markers from different cancer-related genes. By integrating signals from multiple markers (APC, KRAS, TP53, SMAD4) with known differential methylation patterns, the system achieves superior detection accuracy compared to single-marker approaches, while the modular nature of the composite panel keeps the implementation complexity manageable
2Reliability
If DNA methylation markers are used for early detection, then the specificity and accuracy improve, but the complexity of the diagnostic method increases
Solution Approach 1:
The invention replaces complex invasive mechanical procedures (colonoscopy, biopsy) with a less complex molecular analysis approach measuring DNA methylation patterns in circulating tumor DNA. This substitution maintains high reliability for early detection while reducing procedural complexity and patient burden, as methylation status can be determined through biochemical assays rather than invasive imaging or tissue sampling
Solution Approach 2:
The invention shifts the diagnostic parameter from detecting physical presence of tumor cells or gross structural changes to measuring epigenetic methylation status of specific DNA sequences. This parameter change enables detection at earlier stages with higher specificity, as methylation alterations occur before visible tumor formation, while the targeted nature of methylation-specific assays keeps the method complexity controlled
3Measurement precision
If multiple methylation markers are analyzed, then the stratification accuracy of advanced adenoma and colorectal cancer improves, but the cost and complexity of the assay increases
Solution Approach 1:
The invention implements a tiered marker analysis approach where a core panel of high-value markers (APC, KRAS) is always analyzed, and additional markers (TP53, SMAD4) are added based on clinical need and risk stratification requirements. This partial action principle allows the system to achieve high stratification accuracy when needed while maintaining simpler, more cost-effective operation for routine screening, thereby balancing accuracy with assay complexity and cost
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The biomarker panel provides high specificity and accuracy in early detection and stratification of CRC and advanced adenoma, minimizing false positives and negatives.
Implementation Method 1
Deoxyribonucleic acid (DNA) methylation (DNAme) is an important epigenetic marker in diverse species. DNA methylation in vertebrates is characterized by the addition of a methyl or hydroxymethyl group to the C5 position of cytosine, which occurs mainly in the context of CG dinucleotides.
Implementation Method 2
the markers or maker panels made up of the specified markers provide advanced adenoma and/or colorectal cancer screening at high specificity at early or premalignant stage, minimizing the negative and false positive cases when interrogated in samples taken from a subject.
Data Source
AI summary
The present disclosure provides for, among other things, methods and systems for detecting, diagnosing, predicting, monitoring, screening for, staging, and/or providing survival prognosis for advanced adenoma and/or colorectal cancer using DNA methylation markers. For example, described herein are DNA methylation markers that enable categorization and prognosis evaluation of advanced adenoma (AA) and/or colorectal cancer (CRC) patients with high accuracy from human biospecimens.